SH-201 is under clinical development by Shorla Oncology and currently in Pre-Registration for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Pre-Registration drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how SH-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SH-201 overview
Shorla Oncology overview
Shorla Oncology develops and commercializes oncology drugs. The company’s product includes Nelarabine Injection, a generic formulation of nelarabine for the treatment of t-cell acute lymphoblastic leukemia (T-ALL), and t-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients. It is developing its product pipeline that consists of various drug programs such as SH-105 to treat breast and ovarian cancer and brain metastasis in breast cancer; SH-110 for Glioma; and SH-114 to treat myelodysplastic syndromes. Shorla Oncology’s pipeline also includes the SH-201 drug program for the treatment of chronic myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes (MDS), and gastrointestinal tumors. The company operates in Ireland and the US. Shorla Oncology is headquartered in Tipperary, Ireland.
For a complete picture of SH-201’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
